What is Longboard Pharmaceuticals, Inc. (LBPH) stock price today?

Longboard Pharmaceuticals, Inc. (LBPH) is currently trading at $59.98.

What is LBPH P/E ratio?

Longboard Pharmaceuticals, Inc.'s P/E ratio is -25.10. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is LBPH return on equity (ROE)?

Longboard Pharmaceuticals, Inc.'s return on equity (ROE) is -106.30%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Longboard Pharmaceuticals, Inc.'s market cap?

Longboard Pharmaceuticals, Inc. has a market capitalization of $2.34B.

NASDAQ · Biotechnology

Longboard Pharmaceuticals, Inc. (LBPH) Stock

$59.98 NASDAQ: LBPH Healthcare

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm committed to advancing innovative treatments for neurological conditions.

Valuation

Metric	Value
Price	$59.98
Market Cap	$2.34B
P/E Ratio	-25.10
P/B Ratio	33.31
P/S Ratio	0.00
EPS (TTM)	$-2.39
52-Week High	$59.98
52-Week Low	$59.98
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-106.30%
ROA	-107.35%
ROCE	-138.70%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.01
Current Ratio	5.14

Annual Financials (USD)

Metric	2020	2021	2022	2023
Revenue	$0	$0	$0	$0
Operating Profit	$-14.0M	$-28.0M	$-45.0M	$-57.0M
Net Profit	$-14.0M	$-28.0M	$-43.0M	$-54.0M
EPS	$-0.82	$-1.62	$-2.51	$-2.39
Op Margin	—	—	—	—

Balance Sheet (USD)

Metric	2020	2021	2022	2023
Total Assets	$56.0M	$109.0M	$71.0M	$51.0M
Total Liabilities	$3.0M	$6.0M	$9.0M	$10.0M
Cash	$55.0M	$66.0M	$11.0M	$14.0M
Borrowings	$0	$1.0M	$1.0M	$0

Latest News

UK economy claws back some growth as Burnham prepares to take power Reuters · Jul 16, 2026 Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals GlobeNewswire · Jul 16, 2026 Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy MT Newswires · Jul 16, 2026 Asian stocks mostly sink as AI worries hammer tech AFP · Jul 16, 2026 JETEX ENHANCES ITS CSR STRATEGY AND PARTNERS WITH THE WORLD FOOD PROGRAMME GlobeNewswire · Jul 16, 2026

Cash Flow (USD)

Metric	2020	2021	2022	2023
Operating Cash Flow	$-3.0M	$-25.0M	$-38.0M	$-51.0M
Investing Cash Flow	$0	$-41.0M	$-17.0M	$48.0M
Financing Cash Flow	$3.0M	$-8.0M	$0	$-2.0M
Net Cash Flow	$55.0M	$11.0M	$-56.0M	$4.0M
Free Cash Flow	$-3.0M	$-25.0M	$-38.0M	$-51.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-4.43
EV / EBITDA	-41.02
FCF Yield	-2.17%
Quick Ratio	5.14
Interest Coverage	0.00
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BLUBELLUS Health Inc.	$14.75	+0.03%	-22.34	$1.87B	0.00%
CALTCalliditas Therapeutics AB (publ)	$40.00	-0.10%	-22.08	$2.15B	0.00%
DCPHDeciphera Pharmaceuticals, Inc.	$25.59	+0.08%	-11.17	$2.21B	0.00%
DICEDICE Therapeutics, Inc.	$47.55	+0.06%	-22.97	$2.27B	0.00%
FUSNFusion Pharmaceuticals Inc.	$21.55	+0.14%	-14.86	$1.83B	0.00%

About Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm committed to advancing innovative treatments for neurological conditions. Its primary drug candidate, LP352, is currently progressing through a Phase 1b/2a clinical trial, aimed at managing seizures associated with developmental and epileptic encephalopathies. The company also boasts preclinical pipeline candidates, LP659 and LP143, designed to tackle a range of neurological diseases. Incorporated in 2020, the company, formerly known as Arena Neuroscience, Inc., adopted its current name, Longboard Pharmaceuticals, Inc., in October 2020. Its corporate headquarters are situated in La Jolla, California.

Longboard Pharmaceuticals, Inc. is headquartered in US.

Longboard Pharmaceuticals, Inc. (LBPH) stock trades at $59.98 with a market capitalization of $2.34B. The stock is valued at a price-to-earnings (P/E) ratio of -25.10, price-to-book of 33.31, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $59.98 and $59.98, and currently trades at its 52-week high.

On profitability, Longboard Pharmaceuticals, Inc. generates a return on equity (ROE) of -106.30%, return on capital employed of -138.70%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.longboardpharma.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides